FGFR1 and central nervous system cancer: Other, rarer fusions have also been identified, such as FGFR1-TACC1 (Perwein et al., 2021; Bale, 2020) and FGFR2-CTNNA3 (Zhao et al., 2022) fusions are rare events predominantly found in IDH-mutant lower-grade gliomas (≤1%).